Compare Abbott Laboratories (ABT) vs Procter & Gamble Co (PG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Procter & Gamble Co — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Procter & Gamble Co trades at $152.5 (market cap $355.69B). The key difference: Procter & Gamble Co is far larger — about 2.1× Abbott Laboratories's market cap, and Procter & Gamble Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABT | PG | |
|---|---|---|
Market Cap | $166.94B | $355.69B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $167.18 |
52-Week Low | $82.57 | $138.10 |
Enterprise Value | $193.69B | $381.17B |
Dividend Yield | 2.63% | 2.79% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Procter & Gamble (PG) trades at $148.9, down 0.27% on the day, with a bullish technical outlook supported by moving averages and key support at $148. The company reported consistent earnings beats, with Q1 2026 EPS of $1.59 exceeding the $1.56 estimate, and maintains strong cash flow from operations of $17.82B in 2025. Recent developments include a new WNBA partnership and a $1.09 dividend payment scheduled for May 2026.
PG offers stable growth with a 19.16% net income margin and a consensus price target of $159.88, implying 7% upside. Risks include premium valuations (P/E of 22.33) amid modest revenue growth and economic sensitivity. Analyst sentiment is bullish (56% buy ratings), but investors should monitor competitive pressures and inflation impacts on margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
